Fajri Gafar

Fajri Gafar
Verified
Fajri verified their affiliation via an institutional email.
Verified
Fajri verified their affiliation via an institutional email.
  • MPharm PhD
  • Postdoctoral Fellow at McGill University

About

18
Publications
1,978
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
192
Citations
Current institution
McGill University
Current position
  • Postdoctoral Fellow
Additional affiliations
October 2017 - November 2017
University of Groningen
Position
  • ATTP Research Internship
June 2017 - July 2017
University of Groningen
Position
  • ISCOMS Research Internship
June 2017 - December 2017
Universitas Muhammadiyah Prof Dr Hamka
Position
  • Lecturer
Education
April 2018 - April 2022
University of Groningen
Field of study
  • Personalised Medicine and Pharmacogenetics
March 2011 - November 2016
Andalas University
Field of study
  • Clinical Pharmacy
January 2010 - January 2011
Andalas University
Field of study
  • Clinical Pharmacy

Publications

Publications (18)
Article
Full-text available
Background Data on childhood and adolescent multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) in Indonesia are lacking. We aimed to assess clinical features, adverse events (AEs) and treatment outcomes of childhood and adolescent MDR/RR-TB. Methods A retrospective cohort study was performed in children and adolescents aged <18 years treated...
Article
Full-text available
Background: Pharmacokinetic data of rifampin, when used for tuberculosis preventive treatment (TPT) are not available. We aimed to describe the pharmacokinetics of rifampin used for TPT, at standard and higher doses, and to assess predictors of rifampin exposure. Methods: A pharmacokinetic sub-study was performed in Bandung, Indonesia among partic...
Article
Full-text available
Background Pharmacokinetic data on high-dose isoniazid for the treatment of rifampicin-/multidrug-resistant tuberculosis (RR/MDR-TB) are limited. We aimed to describe the pharmacokinetics of high-dose isoniazid, estimate exposure target attainment, identify predictors of exposures, and explore exposure–response relationships in RR/MDR-TB patients....
Article
Full-text available
INTRODUCTION Therapeutic drug monitoring (TDM) could improve TB treatment outcomes by avoiding drug toxicity or underdosing. In this study, we describe the patient burden in three TB centres in Romania and Ukraine with a TDM indication, as per the current guidelines, in order to estimate the feasibility of implementing TDM. METHODS A retrospective...
Article
Full-text available
Background: Suboptimal exposure to antituberculosis drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line antituberculosis drug pharmacokinetics in children and adolescents at a global level. Methods: We systematically searched MEDLINE, Embase, and Web of Science (1990-20...
Article
Full-text available
We retrospectively evaluated clinical features and outcomes in children treated for tuberculous meningitis (TBM) at Hasan Sadikin Hospital, Bandung, Indonesia, during 2011-2020. Among 283 patients, 153 (54.1%) were <5 years of age, and 226 (79.9%) had stage II or III TBM. Predictors of in-hospital death (n = 44 [15.5%]) were stage III TBM, hydrocep...
Article
Full-text available
Objective To assess the pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents with tuberculous meningitis (TBM). Design Prospective observational pharmacokinetic study with an exploratory pharmacokinetic/pharmacodynamic analysis. Setting Hasan Sadikin Hospital, Bandung, Indonesia. Patients...
Article
BACKGROUND: Despite considerable efforts to globally eradicate TB, and the availability of effective antibiotics, TB elimination goals are falling behind. While non-adherence to TB drug regimens may compromise effective treatment, its full impact is still unknown.OBJECTIVE: To determine the clinical and economic impact of non-adherence to TB medica...
Article
Background Tuberculosis (TB) in children and adolescents is a sentinel event for ongoing transmission. In the Netherlands, epidemiological characteristics of childhood and adolescent TB have not been fully evaluated. Therefore, we aimed to assess TB epidemiology within this population to provide guidance for TB elimination. Methods A retrospective...
Article
Background As a vulnerable population, children and adolescents with tuberculosis (TB) are faced with many challenges, even for those who live in low TB incidence countries. We aimed to evaluate factors associated with TB treatment outcomes allowing more focused interventions to support this population once diagnosed. Methods A retrospective cohor...
Article
Background: As one of the most frequent and serious adverse reactions during tuberculosis treatment, antituberculosis drug-induced liver injury (ATLI) in children has been studied insufficiently compared with adults. We aimed to determine the incidence and risk factors of ATLI in children during the first two months of TB-therapy. Methods: A tot...
Article
Full-text available
We performed a post-hoc analysis of the OLiVIA-study investigating whether current and ex-smoking asthmatics with small airways dysfunction (SAD) show a better response in airway hyperresponsiveness (AHR) to small particle adenosine after treatment with extrafine compared to non-extrafine particle inhaled corticosteroids (ICS), and to investigate w...

Network

Cited By